Memorial Sloan Kettering Cancer Center
ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamibarotene + Venetoclax & Azacitidine in RARA+ Newly Diagnosed AML Patients Ineligible for Standard Induction Chemo
By
ASH 2022 Conference Coverage
FEATURING
Eytan Stein
By
ASH 2022 Conference Coverage
FEATURING
Eytan Stein
Login to view comments.
Click here to Login